TABLE 2.
Changes from baseline in clinical variables at week 104 or at premature treatment discontinuation
| Liraglutide – OAD a treatment difference | 95% CI | P value b | |
|---|---|---|---|
| HbA1c (%) | −0.33 | −0.43; −0.23 | <.0001 |
| HbA1c (mmol/mol) | −3.62 | −4.73; −2.52 | <.0001 |
| FPG (mmol/L) | −0.69 | −0.91; −0.46 | <.0001 |
| Body weight (kg) | −0.61 | −1.07; −0.16 | .009 |
| BMI (kg/m2) | −0.22 | −0.38; −0.06 | .007 |
| Systolic blood pressure (mmHg) | 0.24 | −0.89; 1.36 | .68 |
| Diastolic blood pressure (mmHg) | 0.21 | −0.50; 0.91 | .56 |
Abbreviations: BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; OAD, oral antidiabetic drug.
a
OADs included investigator‐selected drugs from the classes: α‐glucosidase inhibitor, dipeptidyl peptidase‐4 inhibitor, sodium‐glucose co‐transporter‐2 inhibitor, sulphonylurea, or thiazolidinedione; both liraglutide and OADs were prescribed in combination with metformin. Full analysis set.
b
Two‐sided P value for test of no treatment difference.